trending Market Intelligence /marketintelligence/en/news-insights/trending/7gmhk0m5qeftkkyyik4h-q2 content esgSubNav
In This List

European regulator accepts Teva application for migraine treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


European regulator accepts Teva application for migraine treatment

The European Medicines Agency accepted marketing authorization application for Teva Pharmaceutical Industries Ltd.'s fremanezumab to treat migraine in adults.

Israel-based Teva said the marketing authorization application was based on data from its Halo trial, which enrolled more than 2,000 patients with episodic and chronic migraine.

Teva also filed an application for the medicine with the U.S. Food and Drug Administration in 2017.